Lilly's Online, Interactive Health Education Program Receives Two Web Awards

LillyLilly USA recently was recognized by the eHealthcare Leadership Awards and the Web Marketing Association for its Health Education Answers program, an interactive health and wellness tool.

Health Education Answers is a free, Web-based program designed to help managed care and public payer organizations further drive the quality of patient care through educational outreach. This tool, which also is available in DVD-ROM format, educates patients on several health areas, including proper diet and exercise, healthy habits to teach children, and simple steps to help individuals and families prevent or manage illness.

At the 13th Annual Healthcare Internet Conference, Health Education Answers received an eHealthcare Leadership Award of Distinction for Best Care/Disease Management Site for the online tool's ability to help consumers manage a chronic condition, encourage two-way communication between patient and health care practitioners, and provide opportunities to monitor clinical care. More than 1,100 entries were received from a wide range of health care organizations, online health companies, pharmaceutical/medical equipment firms, suppliers and business improvement initiatives.

In addition, Health Education Answers received the 2009 Health Care Standard of Excellence Award from the Web Marketing Association. This award recognizes the people and organizations responsible for developing some of the most effective Web sites on the Internet today.

"Lilly is honored to be recognized by both the eHealthcare Leadership Awards and the Web Marketing Association for Health Education Answers," said Alex M. Azar II, vice president, Lilly USA. "These external awards give credibility to the fact that Health Education Answers is an easy-to-use and effective health and wellness program. We're proud to provide managed care and public payer organizations with this educational option that gives their plan members the tools they need to improve and maintain their health."

About Health Education Answers
Available in Spanish and English and with portions in Mandarin, Health Education Answers is based on research-supported patient education material that adheres to national clinical guidelines. Patients accessing the program can progress through several health and disease management modules, including ADHD, Bipolar Disorder, Depression, Diabetes, Diabetes Complications, Heart Health, Manage Your Weight, Medication Safety, Men's Health, Schizophrenia, Smoking and Addictions, Wellness and Women's Health.

The program also includes an optional health risk assessment, which helps patients identify and understand their individual health needs and at-risk behaviors. Based on the results, Health Education Answers directs patients to the most applicable education modules that provide tips for improvement.

The tool can be customized to meet each organization's individual needs, including incorporating the organization's logo, approved color palette, specific content selections and a personalized welcome message.

Other Recognitions
Health Education Answers received the Health on the Net Foundation's Code of Conduct (HONcode) certification. The HONcode is a voluntary certification system that aims to raise the quality of health care information available on the Internet. Health information Web sites that receive HONcode certification have been evaluated by the organization for providing reliable and credible health information, as well as data confidentiality, proper attribution of sources and transparency of financial sponsorship.

In 2008, Health Education Answers received Health Information Product Certification from the National Committee for Quality Assurance (NCQA) in the area of Health Risk Appraisals and Interactive Consumer Health Tools. NCQA is a private, nonprofit organization dedicated to providing health care quality information in order to help consumers, employers and others make more informed health care choices. Lilly is the first and only pharmaceutical company in the nation to receive this NCQA program status.

About Eli Lilly and Company
Eli Lilly and Company, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. For additional information on Health Education Answers or Lilly's other patient care and disease management programs, visit www.lillyforbetterhealth.com.

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

Drug linked to 45% lower risk of dying among COVID…

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be ...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Sanofi and Regeneron provide update on Kevzara┬« (s…

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical v...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Another mRNA-based vaccine candidate protects anim…

An experimental messenger RNA (mRNA)-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits protective immune responses in mice and no...

Pfizer and BioNTech announce an agreement with U.S…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of...

Pfizer and BioNTech announce agreement with the Un…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candid...